Sanofi to market new haemophilia drug in deal with Alnylam

Paris

FRENCH pharmaceutical group Sanofi said it has obtained the right to develop and sell a new haemophilia drug in a restructuring of its partnership with Alnylam Pharmaceuticals.

Under the agreement, Sanofi will obtain global development and commercialisation rights to fitusiran, currently in development for the treatment of people with hemophilia A and B.